HARNESSING THE SKILLSET AND AVAILABILITY OF THE NATION’S EXERCISE PHYSIOLOGISTS AND SCIENTISTS
With
Katie Lyndon, Accredited Exercise Physiologist & CEO
Exercise & Sports Science Australia (ESSA)
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Canberra | March 2026
Katie Lyndon MBA, BAppSci, ESSAF, FACHSM, CHE, AEP, AES, GAICD, CHIA, is an allied health professional and executive leader with nearly two decades of experience spanning executive leadership, delivery of strategic programs across the health system and clinical care. Beginning her career as an Accredited Exercise Physiologist, Katie has held senior roles across Queensland Health, Hospital and Health Services, Deloitte health advisory consulting, Queensland Treasury Corporation, and private practice.
As CEO of Exercise & Sports Science Australia (ESSA), Katie brings a unique blend of frontline experience and strategic vision to advance the profession and advocate for evidence-based exercise in preventive health and chronic disease management. Her long-standing commitment to ESSA includes serving as Board Vice President, Policy and Advocacy Manager, Standards Council member and ESSA Fellow.
Katie is recognised for creating high-performing, values-driven teams and leading innovative health service models.
Source: Supplied
-
Clinical pain neuroscientist talks about how the brain processes pain information
Persistent pain affects one in five Australians and costs the nation an estimated $73 billion per year in health system costs, lost productivity and other financial costs.
Persistent pain also has debilitating personal costs – negatively impacting quality of life and the ability to engage in meaningful work and life activities.
Despite the enormity of this problem, very few effective treatments exist with most showing only small to moderate improvements. New treatments are desperately needed. The group believes the best way to create impactful change is to work with people with lived experience of persistent pain to devise solutions with them, not for them.
-
Improved treatment in advanced-stage Hodgkin lymphoma
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.
-
Breaking silos to transform women’s health through MedTech
In an interview with Australian Health Journal, Jasjit Baveja, Director of Regulatory and Industry Policy at the Medical Technology Association of Australia (MTAA), highlighted the growing importance of medical technology in addressing longstanding inequities in women’s health.
Drawing on the outcomes of the inaugural MTAA Women’s Health MedTech Summit, she explained how the event brought together clinicians, researchers, industry leaders, regulators, investors, government representatives and patient advocates to tackle complex challenges through a collaborative approach.
